Takeda News, Takeda Quote, TAK Quote

Takeda (NY:TAK) Delayed: 20.43 +0.19 (0.94%)

Prev. Close

$20.24

Today 6M 1Y 5Y

Open

$20.40

52 Wk High

$0.55

52 Wk Low

$0.55

Day High

$20.55

Day Low

$20.36

P/E

N/A

EPS

$-0.20

Volume

2,367,367

Friends, Peers and Foes (?): 4502:JP, PTGX, 6IB, IVBIY, ALKS (more...)

ALERTS | RSS

Oct 23, 2026 07:30 AM Takeda's TAK-921 meets dual endpoints in gastric cancer trial
Oct 23, 2026 07:30 AM Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastr
Oct 19, 2026 06:01 AM Takeda Entyvio trial shows disease clearance cuts UC complication risk
Oct 19, 2026 05:30 AM First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Oct 15, 2026 05:58 AM Takeda launches narcolepsy drug Orzeyful in Japan and China
Oct 14, 2026 08:30 PM Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Oct 14, 2026 08:00 AM Takeda's TAK-881 meets primary endpoint in Phase 2/3 PID trial
Oct 14, 2026 08:00 AM Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Sep 30, 2026 01:02 AM Takeda psoriasis drug outperforms deucravacitinib in phase 3 trial
Sep 30, 2026 01:01 AM Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Entities mentioned with TAK

View All Entities